Sanofi Pasteur

sanofi pasteur
Public
Founded August 2004 by merger
Headquarters Lyon, France
Key people
Olivier Charmeil Executive Vice President, Vaccines
Parent Sanofi
Slogan Because health matters. (French: L'essentiel c'est la santé.)
Website sanofipasteur.com

Sanofi Pasteur is the vaccines division of the multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines.

History

In 1994, Aventis merged with and into Sanofi. The new Sanofi-Aventis Group became the world's 3rd largest pharmaceutical company. Aventis Pasteur, the vaccine division[1] of Sanofi-Aventis Group, changed its name to Sanofi Pasteur.[2] In 2014, Sanofi Pasteur stopped producing its effective Fav-Afrique antivenom because competition from cheaper though less powerful competitors made it unprofitable.[3] Doctors Without Borders said that it would take two years to develop a similar antivenom, and that existing stocks will run out in June 2016.[3]

Key dates

Key facts & figures in 2012

Sanofi Pasteur

Vaccines

2012 BCG supply shortage

Main article: BCG vaccine

In the fall of 2011 the Sanofi Pasteur plant flooded causing problems with mold.[11] The facility, located in Toronto, Ontario, Canada, produced BCG vaccine products, made with the Glaxo 1077 strain,[12] such as a tuberculosis vaccine ImmuCYST, a BCG Immunotherapeutic -a bladder cancer drug. By April 2012 the FDA had found dozens of documented problems with sterility at the plant including mold, nesting birds and rusted electrical conduits.[11] The resulting closure of the plant for over two years resulting in shortages of bladder cancer and tuberculosis vaccines.[13] The Toronto Sanofi plant [14] On October 29, 2014 Health Canada gave the permission for Sanofi to resume production of BCG.[15]

External links

References

  1. "Sanofi Pasteur Vaccine Hub". www.vaccinehub.com.au. Retrieved 1 March 2014.
  2. "sanofi-aventis : Sanofi Pasteur, the vaccine division of the Sanofi-aventis Group, changes its name to sanofi pasteur". Retrieved 2007-11-04.
  3. 1 2 Associated Press (7 September 2015). "Snakebite anti-venom running out worldwide, MSF". CBC News. Retrieved 8 September 2015.
  4. "Why vaccinate?". www.vaccinehub.com.au. Retrieved 1 March 2014.
  5. "Connaught and the Canadian Polio Vaccine Story +". CONNTACT, June 1996 (Vol. 9 No. 3) (Employee News of Connaught Laboratories Limited). Retrieved 11 December 2012.
  6. http://www.thehindubusinessline.com/companies/article2101029.ece
  7. http://www.sanofipasteur.us/
  8. http://www.sanofi.fr/l/fr/fr/layout.jsp?cnt=78E1307E-31BC-4815-AF98-4778BF224148
  9. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 "Sanofi Pasteur US Products". Retrieved 2007-12-04.
  10. Staff Writer (25 April 2011). "FDA Grants Licensure To Expand Indication For Sanofi Pasteur's Menactra". RTTNews. Retrieved 26 April 2011.
  11. 1 2 "April 2012 Inspectional Observations (form 483)", U.S. Food and Drug Administration, Vaccines, Blood & Biologics, April 12, retrieved 29 January 2016 Check date values in: |date= (help)
  12. Fine, P.E.M (2004). Issues relating to the use of BCG in immunization programmes: A discussion document, WHO/V&B/99.23 (PDF). Geneva: WHO.
  13. Palmer, Eric (10 September 2014), "Merck again shipping BCG cancer treatment but Sanofi still is not: Shortages of bladder cancer and tuberculosis treatment have persisted for two years", FiercePharma
  14. Palmer, Eric (12 July 2012), "Merck again shipping BCG cancer treatment but Sanofi still is not: Shortages of bladder cancer and tuberculosis treatment have persisted for two years", FiercePharma
  15. Palmer, Eric (31 March 2015), "Sanofi Canada vax plant again producing ImmuCyst bladder cancer drug", FiercePharma, retrieved 29 January 2016
This article is issued from Wikipedia - version of the Friday, January 29, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.